Identification of Risk Factors Parkinson's Disease by Convergence Strategy

Identification of Risk Factors Parkinson's Disease by Convergence Strategy

Patrocinadores

Patrocinador principal: University Hospital, Lille

Fuente University Hospital, Lille
Resumen breve

Using this convergence approach from a limited group of subjects with non-diseased controls, patients with Parkinson's disease or related diseases, we will be able to limit the number of potential genes of specific susceptibility to Parkinson disease. These genes will then be studied using a case-control genetic epidemiology approach. The risk of developing the disease will then be evaluated according to clinical, biological and environmental variables collected in Parkinson's subjects and healthy controls in the second group of subjects. The specificity of the genetic associations found will be evaluated in subjects with Parkinson's disease.

Estado general Recruiting
Fecha de inicio March 25, 2009
Fecha de Terminación March 2024
Fecha de finalización primaria March 2024
Tipo de estudio Observational
Resultado primario
Medida Periodo de tiempo
Significant variations in the frequencies of gene polymorphisms and the risk of developing Parkinson's disease through study completion, an average of 10 years
Inscripción 2220
Condición
Elegibilidad

Método de muestreo: Probability Sample

Criterios:

Inclusion Criteria:

- Inclusion criteria for Parkinson's patients and "related diseases" controls:

- Parkinsonian patients meeting the Gelb criteria

- Patients with other neurodegenerative disease (such as other Parkinson syndrome or synucleopathies) meeting the criteria set out in Appendix 2 (Lewy Bodies dementia, Parkinson's disease with dementia, MultiSystem atrophy, Progressive Supranuclear Paralysis) , Amyotrophic Lateral Sclerosis, Restless Legs Syndrome, Alzheimer's Disease).

- Woman of childbearing age having an effective means of contraception.

- Informed consent signed by the subject or his legal representative.

- For demented subjects coming for consultation or day hospitalization with an accompanying person, signature of the legal representative.

Criteria for inclusion of non-ill controls:

- Absence of rest trembling, bradykinesia and stiffness

- MMSE (Mini Mental State Examination) greater than 25

- Woman of childbearing age having an effective means of contraception.

- subject having signed the informed consent.

- No family history of neurodegenerative disease that started before age 70. These controls will not present any Parkinsonian signs during the clinical evaluation. They may have functional disabilities whose cause is known and unrelated to a neurodegenerative disease with a cognitive function measurement greater than 25 in the MMSE test.

Exclusion Criteria:

- Criteria for non-inclusion of patients:

- Clinical criteria for exclusion of the diseases described

- Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.

Criteria for non-inclusion of non-ill controls:

- Functional discomfort in daily life of unknown cause

- MMSE less than 25

- Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.

Género: All

Edad mínima: 18 Years

Edad máxima: N/A

Voluntarios Saludables: Accepts Healthy Volunteers

Oficial general
Apellido Papel Afiliación
Alain DESTEE, MD, PhD Principal Investigator University Hospital, Lille
Contacto general

Apellido: Alain DESTEE, MD,PhD

Email: [email protected]

Ubicación
Instalaciones: Estado: Investigador: Hôpital Roger Salengro, CHRU de Lille Alain DESTEE, MD,PhD Principal Investigator
Ubicacion Paises

France

Fecha de verificación

August 2020

Fiesta responsable

Tipo: Sponsor

Tiene acceso ampliado No
Condición Examinar
Grupo de brazo

Etiqueta: Controls

Descripción: This group will include "healthy" person.

Etiqueta: Parkinson's patient

Descripción: This group will include Parkinsonian patients

Etiqueta: patients with a related disease.

Descripción: This group will include patients with a related disease.

Acrónimo CONVERGENCE
Datos del paciente No
Información de diseño del estudio

Modelo de observación: Case-Control

Perspectiva de tiempo: Prospective

Fuente: ClinicalTrials.gov